Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Solid Tumours

SCT for Wilms’ tumour

Bone Marrow Transplantation volume 41, pages S128–S130 (2008)Cite this article

Abstract

Thanks to advances in treatment, approximately 85–90% of patients suffering from Wilms’ tumour are now cured. However, success rate after relapse is significantly lower, ranging from 25 to 45%. Several different re-induction approaches, more or less intensive according to first-line therapy and characteristics of relapse, have been proposed. A number of adverse prognostic factors related to a bad outcome after relapse have been identified and are used as inclusion criteria for entering in a programme including high-dose chemotherapy (HCT). HCT followed by autologous haematopoietic stem cell rescue has been used in small numbers of patients worldwide and promising results have been reported. Information from the European Group for Blood and Marrow Transplantation Database regarding more than 300 transplants have been gathered. In addition, literature data on rescue therapy and HCT will be discussed, such as recent treatment proposals currently under discussion within European and US cooperative groups.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Metzger ML, Dome JS . Current therapy for Wilms’ tumor. Oncologist 2005; 10: 815–826.

    Article  CAS  Google Scholar 

  2. Pein F, Rey A, de Kraker J, Ludwig R, Pötter R, Godzinsky J et al. Multivariate analysis of adverse prognostic factors (APF) in children with recurrent (Rec) Wilms’ tumor (WT) after initial treatment according to SIOP-6 or SIOP-9 strategies. Med Pediatr Oncol 1999; 33: 170 (abstract no. 111).

    Google Scholar 

  3. Grundy P, Breslow N, Green DM, Sharples K, Evans A, D’Angio GJ . Prognostic factors for children with recurrent Wilms’ Tumor: results from the second and third National Wilms’ Tumor Study. J Clin Oncol 1989; 7: 638–647.

    Article  CAS  Google Scholar 

  4. Dome JS, Liu T, Krasin M, Lott L, Shearer P, Daw NC et al. Improved survival for patients with recurrent Wilms tumor: the experience at St Jude Children's Research Hospital. J Pediatr Hematol Oncol 2002; 24: 192–198.

    Article  Google Scholar 

  5. Pein F, Tournade MF, Zucker JM, Brunat-Mentigny M, Deville A, Boutard P et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms’ tumor—a phase II study by the French Society of Pediatric Oncology. J Clin Oncol 1994; 12: 931–936.

    Article  CAS  Google Scholar 

  6. Abu-Ghosh AM, Krailo MD, Goldman SC, Slack RS, Davenport V, Morris E et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms’ tumor: a Children's Cancer Group report. Ann Oncol 2002; 13: 460–469.

    Article  CAS  Google Scholar 

  7. Garaventa A, Hartmann O, Bernard JL, Zucker JM, Pardo N, Castel V et al. Autologous bone marrow transplantation for pediatric Wilms’ tumor: the experience of the European bone marrow transplantation solid tumor registry. Med Pediatr Oncol 1994; 22: 11–14.

    Article  CAS  Google Scholar 

  8. Kullendorff CM, Bekassy AN . Salvage treatment of relapsing Wilms’ tumour by autologous bone marrow transplantation. Eur J Pediatr Surg 1997; 7: 177–179.

    Article  CAS  Google Scholar 

  9. Pein F, Michon J, Valteau-Couanet D, Quintana E, Frappaz D, Vannier JP et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms’ tumor: A French Society of Pediatric Oncology Study. J Clin Oncol 1998; 16: 3295–3301.

    Article  CAS  Google Scholar 

  10. Kremens B, Gruhn B, Klingebiel T, Hasan C, Laws HJ, Koscielniak E et al. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant 2002; 30: 893–898.

    Article  CAS  Google Scholar 

  11. Campbell AD, Cohn SL, Reynolds M, Seshadri R, Morgan E, Geissler G et al. Treatment of relapsed Wilms’ tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital. J Clin Oncol 2004; 22: 2885–2890.

    Article  CAS  Google Scholar 

  12. Spreafico F, Bisogno G, Collini P, Jenkner A, Gandola L, D’Angelo P et al. Treatment of high-risk relapsed wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell. Support: Experience by the Italian Association of Pediatric Hematology and Oncology. Pediatr Blood Cancer doi: 10.1002/pbc.21524.

Download references

Acknowledgements

We thank Sara Calmanti for her assistance in editing the paper and Mrs Valerie Perricone for reviewing the text. This study has been supported in part by the Italian Ministry of Health, Programma di Ricerca Finalizzata ex articolo 12 D.L.gs 502/92 2005 ‘Assistenza Domiciliare in Bambini ed Adulti affetti da Patologie Emato-Oncologiche’.

Author information

Authors and Affiliations

  1. Istituto di Ricovero e Cura a Carattere Scientifico, Genoa, Italy

    S Dallorso, G Dini & M Faraci

  2. Istituto Nazionale per lo Studio e la Cura dei Tumori di Milano, Milan, Italy

    F Spreafico

Authors
  1. S Dallorso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Dini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Faraci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Spreafico
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the EBMT Paediatric Working Party

Corresponding author

Correspondence to S Dallorso.

Additional information

Conflict of interest

None of the authors declared any financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dallorso, S., Dini, G., Faraci, M. et al. SCT for Wilms’ tumour. Bone Marrow Transplant 41 (Suppl 2), S128–S130 (2008). https://doi.org/10.1038/bmt.2008.70

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.70

Keywords

This article is cited by

Search

Advanced search

Quick links